Administration of polyethylene glycol in critically ill patients with acute myocardial infarction: a retrospective propensity score-matched cohort study.

IF 2.7 3区医学 Q3 PHARMACOLOGY & PHARMACY

European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-31 DOI:10.1007/s00228-025-03892-w

Linfeng Xie

{"title":"Administration of polyethylene glycol in critically ill patients with acute myocardial infarction: a retrospective propensity score-matched cohort study.","authors":"Linfeng Xie","doi":"10.1007/s00228-025-03892-w","DOIUrl":null,"url":null,"abstract":"Purpose: Polyethylene glycol (PEG) is commonly administered in acute myocardial infarction (AMI) cases, though its clinical efficacy remains unclear. This study investigated whether PEG treatment enhances survival outcomes in AMI patients.Methods: This retrospective study analyzed data from the American Medical Information Mart for Intensive Care (MIMIC)-IV database, examining critically ill patients with AMI. The exposure was defined as PEG administration during hospitalization. The primary endpoints were 7-day and in-hospital all-cause mortality. External validation was performed using the eICU 2.0 database.Results: The study included 2422 participants before propensity score matching (PSM) and 1730 after matching. Multivariate Cox regression analysis prior to PSM revealed that PEG administration significantly lowered 7-day (HR = 0.247, 95% CI 0.179-0.341, p < 0.001) and in-hospital (HR = 0.422, 95% CI 0.347-0.512, p < 0.001) all-cause mortality. Post-PSM analysis produced consistent findings, with PEG administration linked to reduced 7-day (HR = 0.244, 95% CI 0.168-0.354, p < 0.001) and in-hospital (HR = 0.420, 95% CI 0.337-0.524, p < 0.001) mortality. Subgroup analyses indicated PEG's protective effect persisted across all clinical subgroups (all p-interaction > 0.005). External validation using Cox regression further confirmed that PEG administration significantly reduced both in-ICU (HR = 0.353, 95% CI 0.211-0.591, p < 0.001) and in-hospital (HR = 0.403, 95% CI 0.268-0.607, p < 0.001) mortality.Conclusion: PEG administration improved survival outcomes in critically ill AMI patients, reducing both 7-day and in-hospital all-cause mortality.","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1481-1491"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-025-03892-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Polyethylene glycol (PEG) is commonly administered in acute myocardial infarction (AMI) cases, though its clinical efficacy remains unclear. This study investigated whether PEG treatment enhances survival outcomes in AMI patients.

Methods: This retrospective study analyzed data from the American Medical Information Mart for Intensive Care (MIMIC)-IV database, examining critically ill patients with AMI. The exposure was defined as PEG administration during hospitalization. The primary endpoints were 7-day and in-hospital all-cause mortality. External validation was performed using the eICU 2.0 database.

Results: The study included 2422 participants before propensity score matching (PSM) and 1730 after matching. Multivariate Cox regression analysis prior to PSM revealed that PEG administration significantly lowered 7-day (HR = 0.247, 95% CI 0.179-0.341, p < 0.001) and in-hospital (HR = 0.422, 95% CI 0.347-0.512, p < 0.001) all-cause mortality. Post-PSM analysis produced consistent findings, with PEG administration linked to reduced 7-day (HR = 0.244, 95% CI 0.168-0.354, p < 0.001) and in-hospital (HR = 0.420, 95% CI 0.337-0.524, p < 0.001) mortality. Subgroup analyses indicated PEG's protective effect persisted across all clinical subgroups (all p-interaction > 0.005). External validation using Cox regression further confirmed that PEG administration significantly reduced both in-ICU (HR = 0.353, 95% CI 0.211-0.591, p < 0.001) and in-hospital (HR = 0.403, 95% CI 0.268-0.607, p < 0.001) mortality.

Conclusion: PEG administration improved survival outcomes in critically ill AMI patients, reducing both 7-day and in-hospital all-cause mortality.

查看原文本刊更多论文

聚乙二醇在急性心肌梗死危重患者中的应用：回顾性倾向评分匹配队列研究

目的：聚乙二醇（PEG）常用于急性心肌梗死（AMI）病例，但其临床疗效尚不清楚。本研究探讨PEG治疗是否能提高AMI患者的生存结局。方法：本回顾性研究分析了美国重症监护医疗信息市场(MIMIC)-IV数据库的数据，检查了AMI危重患者。暴露定义为住院期间给药PEG。主要终点为7天和院内全因死亡率。使用eICU 2.0数据库进行外部验证。结果：倾向评分匹配前共纳入2422人，匹配后共纳入1730人。多因素Cox回归分析显示，PSM前给药PEG可显著降低7天生存率（HR = 0.247, 95% CI 0.179-0.341, p 0.005）。Cox回归的外部验证进一步证实，使用PEG可显著降低icu内患者的死亡率（HR = 0.353, 95% CI 0.211-0.591, p）。结论：使用PEG可改善危重急性心肌梗死患者的生存结局，降低7天及院内全因死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Pharmacology 医学-药学

CiteScore

5.40

自引率

3.40%

发文量

170

审稿时长

3-8 weeks

期刊介绍： The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.